Table 1.

Final attribute levels developed for presentation in hypothetical GLP-1 RA-like profiles

Level as presented to respondents	Rationale
Mode and frequency of administration
Tablet taken once per day, at least 30 min before the first meal or drink of the day and taking other oral medications	Oral administration of semaglutide
Injection taken once per week, from a single-use pre-filled injection pen	Administration of dulaglutide
Injection taken once per day, from a multiple-use pre-filled injection pen	Administration of liraglutide
Change in HbA1c
On average, patients achieve a 2.0%-point reduction in HbA1c level over 6 months of treatment	Highest HbA1c reduction seen at 26 weeks in PIONEER 9 or PIONEER 10 trial dataa
On average, patients achieve a 1.8%-point reduction in HbA1c level over 6 months of treatment	Hypothetical value
On average, patients achieve a 1.6%-point reduction in HbA1c level over 6 months of treatment	Hypothetical value
On average, patients achieve a 1.4%-point reduction in HbA1c level over 6 months of treatment	Lowest HbA1c reduction seen at 26 weeks in PIONEER 9 or PIONEER 10 trial dataa
Change in weight
On average, patients experience a weight loss of 2.4 kg over 6 months of treatment	“Most favourable” weight change seen at 26 weeks in PIONEER 9 or PIONEER 10 trial dataa
On average, patients experience a weight loss of 1.5 kg over 6 months of treatment	Hypothetical value
On average, patients experience a weight loss of 0.6 kg over 6 months of treatment	Hypothetical value
On average, patients experience a weight gain of 0.3 kg over 6 months of treatment	“Least favourable” weight change seen at 26 weeks in PIONEER 9 or PIONEER 10 trial dataa
Risk of nausea
When beginning to take this medicine, 9 out of 100 patients feel transient nausea (without vomiting)	Highest nausea rate reported in PIONEER 9 or PIONEER 10 trial data
When beginning to take this medicine, 6 out of 100 patients feel transient nausea (without vomiting)	Hypothetical value
When beginning to take this medicine, 4 out of 100 patients feel transient nausea (without vomiting)	Hypothetical value
When beginning to take this medicine, 2 out of 100 patients feel transient nausea (without vomiting)	Lowest nausea rate reported in PIONEER 9 or PIONEER 10 trial data

GLP-1 RA glucagon-like peptide 1 receptor agonist, HbA_1c glycated haemoglobin

^aEfficacy outcome levels (for HbA_1c change and weight change attributes) were based on the trial product estimand. Data from treatment arms that were irrelevant for the survey (orally administered semaglutide 3 mg, and placebo) were disregarded